GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: CervarixDrug: Placebo
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 961
- Registration Number
- NCT00541970
- Locations
- π©πͺ
GSK Investigational Site, Hamburg, Germany
A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2010-05-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00540501
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540436
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
- Conditions
- Healthy SubjectsAndrogen Deficiency
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT00540553
- Locations
- πΊπΈ
GSK Investigational Site, Evansville, Indiana, United States
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
- Conditions
- Neoplasms, Colorectal
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540943
- Locations
- π«π·
GSK Investigational Site, Toulouse, France
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
- Conditions
- Osteoporosis
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540878
- Locations
- πΊπΈ
GSK Investigational Site, Port Orange, Florida, United States
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Purpura, Thrombocytopenic, IdiopathicChronic Idiopathic Thrombocytopenic Purpura
- Interventions
- Drug: SB-497115-GR 12.5mgDrug: SB-497115-GR 12.5mg matching placeboDrug: SB-497115-GR 25mgDrug: SB-497115-GR 50 mg
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2011-03-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00540423
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
- Conditions
- Influenza
- Interventions
- Biological: GlaxoSmithKline Biologicals' influenza vaccine GSK576389ABiological: Fluarix
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2007
- Registration Number
- NCT00540592
- Locations
- π¬π§
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
Study to Evaluate an Influenza Vaccine Candidate
- Conditions
- Influenza
- Interventions
- Biological: Influenza Vaccine GSK1247446A - 4 different formulationsBiological: Fluarixβ’
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1006
- Registration Number
- NCT00540228
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
Effect of GSK704838 In Healthy Volunteers
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00539825
- Locations
- π¬π§
GSK Investigational Site, Harrow, Middlesex, United Kingdom